Publication: The effect of montelukast on bronchial hyperreactivity and lung function in asthmatic children aged 6-13 years
5
Issued Date
2011-06-01
Resource Type
ISSN
22288694
0125877X
0125877X
Other identifier(s)
2-s2.0-79959360949
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Asian Pacific Journal of Allergy and Immunology. Vol.29, No.2 (2011), 127-133
Suggested Citation
Nualanong Visitsunthorn, Varakorn Chirdjirapong, Satit Santadilog, Panjama Pajarn, Orathai Jirapongsananuruk, Chulaluk Komoltri, Pakit Vichyanond The effect of montelukast on bronchial hyperreactivity and lung function in asthmatic children aged 6-13 years. Asian Pacific Journal of Allergy and Immunology. Vol.29, No.2 (2011), 127-133. Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/12040
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
The effect of montelukast on bronchial hyperreactivity and lung function in asthmatic children aged 6-13 years
Other Contributor(s)
Abstract
Background: Cysteinyl leukotrienes have been shown to play an important role in the pathogenesis of asthma. The effect of the leukotriene receptor antagonist, montelukast, on bronchial hyperreactivity (BHR) as measured by the methacholine challenge test in school children has not been reported. Objective: To determine the effect of montelukast (Singulair®) on BHR measured by methacholine challenge and lung function tests in Thai asthmatic children aged 6-13 years. Materials and methods: This was a randomized, double-blind, placebo-controlled, crossover study performed in 29 mild to moderate persistent asthmatic children aged 6-13 years. Each child received crossover treatment with 6 weeks of montelukast (5 mg/day) and 6 weeks of placebo separated by a two-week washout period. Results: The improvement of FEV1 and FEV1/FVC after 6 weeks of treatment was significantly higher in montelukast group compared to those of placebo group (p < 0.05). After 6 weeks of treatment, mean PC20 (+ SEM) in the placebo group (5.7 + 1.41 mg/ml) was lower than in montelukast group (6.8 + 1.74 mg/ml) but there was no significant difference (p = 0.79). Conclusion: Montelukast significantly improved FEV1 and FEV1/FVC but not BHR in mild to moderate persistent asthmatic children aged 6-13 years after the 6 weeks of treatment.